ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. Dokkyo Journal of Medical Sciences
  2. 48(1) 2021

Treatment with Both Nintedanib and Steroid in Bleomycin-induced Pulmonary Fibrosis Model Mice didn’t Inhibit Lung Fibrosis

https://dmu.repo.nii.ac.jp/records/2501
https://dmu.repo.nii.ac.jp/records/2501
2c648f69-8706-4c8f-acbf-b31c91e0c7af
名前 / ファイル ライセンス アクション
DJMS-48-1-3.pdf DJMS-48-1-Shiromori-本文 (2.5 MB)
Item type 学術雑誌論文 / Journal Article(1)
タイトル
タイトル Treatment with Both Nintedanib and Steroid in Bleomycin-induced Pulmonary Fibrosis Model Mice didn’t Inhibit Lung Fibrosis
言語
言語 eng
キーワード
言語 en
主題Scheme Other
主題 nintedanib
キーワード
言語 en
主題Scheme Other
主題 steroid
キーワード
言語 en
主題Scheme Other
主題 bleomycin-induced pulmonary fibrosis
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_6501
資源タイプ journal article
著者 Shiromori, Sadaaki

× Shiromori, Sadaaki

en Shiromori, Sadaaki

Search repository
Hirata, Hirokuni

× Hirata, Hirokuni

en Hirata, Hirokuni

Search repository
Sato, Kozo

× Sato, Kozo

en Sato, Kozo

Search repository
Tada, Kazuhiro

× Tada, Kazuhiro

en Tada, Kazuhiro

Search repository
Arima, Masafumi

× Arima, Masafumi

en Arima, Masafumi

Search repository
Fukushima, Yasutsugu

× Fukushima, Yasutsugu

en Fukushima, Yasutsugu

Search repository
著者所属(英)
言語 en
値 Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University Saitama Medical Center, 2-1-50 Minamikoshigaya, Koshigaya, Saitama 343-0845, Japan
著者所属(英)
言語 en
値 Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University Saitama Medical Center, 2-1-50 Minamikoshigaya, Koshigaya, Saitama 343-0845, Japan
著者所属(英)
言語 en
値 Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University Saitama Medical Center, 2-1-50 Minamikoshigaya, Koshigaya, Saitama 343-0845, Japan
著者所属(英)
言語 en
値 Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University Saitama Medical Center, 2-1-50 Minamikoshigaya, Koshigaya, Saitama 343-0845, Japan
著者所属(英)
言語 en
値 Department of Rheumatology, Dokkyo Medical University, Tochigi, Japan.
著者所属(英)
言語 en
値 Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University Saitama Medical Center, 2-1-50 Minamikoshigaya, Koshigaya, Saitama 343-0845, Japan
書誌情報 Dokkyo Journal of Medical Sciences

巻 48, 号 1, p. 9-21, 発行日 2021-03-25
要旨(英)
内容記述タイプ Other
内容記述 Background:In the clinical setting, the optimal timing of administration of nintedanib in the active or inactive phase of idiopathic pulmonary fibrosis (IPF) has not been clarified. Also, no consideration has been made of synergistic actions with steroids.
Objectives:We used bleomycin-induced pulmonary fibrosis model mice to analyze the effects of the timing of nintedanib administration and synergistic actions in combination with steroids.
Method:In the bleomycin-induced pulmonary fibrosis mouse model, nintedanib was given before or after bleomycin administration and the effects on pulmonary fibrosis and fibroblast growth factors in bronchoalveolar lavage (BAL) fluid were analyzed. Then, treatment with both steroid and nintedanib was administered in the same model and the effects of combined use on lung fibrosis were analyzed. Severity of lung fibrosis was analyzed using the Ashcroft score. Fibroblast growth factors in BAL fluid were measured using Magnetic Luminex® assay and enzyme-linked immunosorbent assay.
Results:Pretreatment with nintedanib before administration of bleomycin, but not after administration of bleomycin, reduced the Ashcroft score (2.4±1.4 vs 4.9±1.3, P<0.01) and decreased TGF-b 1 in BAL fluid (95.7±48.4 pg/mL vs 147.1±11.7 pg/mL, P<0.05). Conversely, pretreatment with both steroid and nintedanib did not decrease the Ashcroft score compared with pretreatment of saline as a control( Score:3.8±1.3 vs 4.6±1.1). There was also no synergistic effect of both steroid and nintedanib on pulmonary fibrosis.
Conclusions:Nintedanib may be useful when administered early in patients with IPF. Further more, clinical administration of combined nintedanib and steroid requires caution in view of the effects on pulmonary fibrosis and side effects.
記事種別
値 Original
出版者
出版者 獨協医学会
ISSN
収録物識別子タイプ ISSN
収録物識別子 03855023
書誌レコードID
収録物識別子タイプ NCID
収録物識別子 AA00629581
戻る
0
views
See details
Views

Versions

Ver.1 2023-06-20 15:21:25.549787
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3